Wells Fargo & Company Catalyst Biosciences, Inc. Transaction History

Wells Fargo & Company

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.33 - $0.65 $3 - $7	11 Added 5.79%	201 $0
Q2 2023 Aug 15, 2023	BUY	$0.2 - $0.35 $1 - $2	7 Added 3.83%	190 $0
Q1 2023 May 12, 2023	BUY	$0.19 - $0.64 $0 - $1	3 Added 1.67%	183 $0
Q4 2022 Feb 13, 2023	BUY	$0.49 - $0.57 $1 - $2	4 Added 2.27%	180 $0
Q3 2022 Nov 14, 2022	SELL	$0.49 - $1.95 $9 - $39	-20 Reduced 10.2%	176 $0
Q2 2022 Aug 12, 2022	SELL	$0.36 - $1.78 $102 - $505	-284 Reduced 59.17%	196 $0
Q1 2022 May 16, 2022	BUY	$0.51 - $1.0 $0 - $1	1 Added 0.21%	480 $0
Q3 2021 Nov 15, 2021	SELL	$3.78 - $5.18 $86 - $119	-23 Reduced 4.58%	479 $2,000
Q2 2021 Aug 16, 2021	SELL	$4.1 - $5.33 $228,517 - $297,072	-55,736 Reduced 99.11%	502 $2,000
Q1 2021 May 13, 2021	SELL	$4.93 - $7.15 $48,042 - $69,676	-9,745 Reduced 14.77%	56,238 $283,000
Q4 2020 Feb 09, 2021	BUY	$4.55 - $7.29 $200,418 - $321,109	44,048 Added 200.81%	65,983 $416,000
Q3 2020 Nov 05, 2020	BUY	$4.22 - $6.04 $44,461 - $63,637	10,536 Added 92.43%	21,935 $94,000
Q2 2020 Aug 13, 2020	BUY	$3.76 - $8.01 $33,794 - $71,993	8,988 Added 372.79%	11,399 $67,000
Q1 2020 May 14, 2020	BUY	$3.5 - $8.51 $8,438 - $20,517	2,411 New	2,411 $10,000

215

Ticker CBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,477,100
Description
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.